sample_abstracts.json

[
    {
        "pmid": "35461811",
        "title": "Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine",
        "abstract": "The BNT162b2 mRNA vaccine has shown high efficacy in preventing COVID-19. We conducted a phase 3 trial to evaluate the safety and immunogenicity of BNT162b2 in healthy adults. Participants received two doses of the vaccine 21 days apart. The primary endpoints were solicited local and systemic reactions within 7 days after each dose and serologic responses. The vaccine was well tolerated with mild to moderate side effects. Strong antibody responses were observed in all age groups."
    },
    {
        "pmid": "34325005",
        "title": "Comparative effectiveness of mRNA and viral vector vaccines",
        "abstract": "This retrospective cohort study compared the effectiveness of mRNA vaccines (BNT162b2 and mRNA-1273) with viral vector vaccines (ChAdOx1 and Ad26.COV2.S) against SARS-CoV-2 infection. We analyzed data from 2.5 million vaccinated individuals. Both vaccine types showed high effectiveness against severe COVID-19, with mRNA vaccines showing slightly higher effectiveness against symptomatic infection. The DTP vaccine was used as a negative control in our analysis."
    },
    {
        "pmid": "33301246",
        "title": "Long-term immunity following SARS-CoV-2 infection",
        "abstract": "We investigated the durability of immune responses in COVID-19 convalescent individuals. Memory B cells specific for the spike protein and neutralizing antibodies persisted for at least 8 months post-infection. T cell responses remained robust, with both CD4+ and CD8+ T cells showing reactivity to multiple SARS-CoV-2 epitopes. These findings suggest that natural infection induces durable immunity that may protect against reinfection."
    }
]